A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD

Status:
RECRUITING

Trial end date:
2024-07-29

Target enrollment:

Participant gender:

The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.

PHASE2

Gilgamesh Pharmaceuticals